Effectiveness and safety of sofosbuvir/ledipasvir?±?ribavirin treatment in liver and/or renal transplant patients with chronic hepatitis C: A single-center experience:

摘要

Objective:Successful treatment is possible with novel direct-acting oral antiviral agents in solid organ transplant patients with hepatitis C. In this study, the effectiveness and safety of sofosbuvir/ledipasvir?±?ribavirin treatment in liver and/or renal transplant patients with chronic hepatitis C were evaluated.Materials and methods:A total of 23 liver and/or renal transplant patients who received sofosbuvir/ledipasvir?±?ribavirin for chronic hepatitis C over 12 or 24?weeks were enrolled in the study. The treatment response, clinical and laboratory adverse effects, and effect on immunosuppressive drug levels were assessed.Results:A total of 12 patients had undergone renal transplantation and 11 had undergone liver transplantation. All of the renal transplant patients and 91% of liver transplant patients had genotype 1. In total, 10 renal transplant patients and 4 liver transplant patients had treatment experience. Two renal transplant patients and one liver transplant patient had compensated cirrhosis....